Increase in Pipeline Regenerative Medicines to Help the Regenerative Medicines Market in the US Grow at a CAGR of Over 33% Until 2020, Says Technavio

LONDON--()--According to the latest research study released by Technavio, the regenerative medicine market in the US is expected to reach over USD 6973 million by 2020.

This research report titled ‘Regenerative Medicine Market in the US 2016-2020’, provides an in-depth analysis of market growth in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts of market segments, including cell therapy and scaffold.

Request sample report: http://bit.ly/1PHeKNG

“The regenerative medicine market in US is slated to witness the launch of new therapies during the forecast period. There are many regenerative medicines in the pipeline that are in different stages of development, ranging from discovery and pre-clinical phase, to the mid and late-stages. There are many new advancements in terms of drug manufacture, development, and delivery expected to follow during the same period. With this, the future landscape of this market is expected to be promising, with many novel products expected to revolutionize the US regenerative medicines market,” said Brahadeesh Chandrasekaran, one of Technavio’s lead analysts for orthopedics and general medical devices research.

“Many cell therapy products based on mesenchymal stem cells are available in the market because of their self-renewal abilities that help develop tissues. The discovery of novel scaffolds and various other growth and control factors have also shown promising results in stimulating tissue formation. These developments are therefore resulting in a gradual shift in focus to regenerative therapies over conventional methods of treatment,” added Brahadeesh.

Segmentation of regenerative medicine market by application 2015

Dermatology – 51.2%
Musculoskeletal – 38.9%
Ocular – 7.7%
Cardiovascular – 2.2%

Top three segments of the global regenerative medicine market:

Dermatology: largest segment of the global regenerative medicine market

The dermatology segment accounted for around 51.2% of the market in 2015 and includes burns and chronic wounds. The treatment of burns and chronic wounds requires a quick response, and skin grafting in most cases. Regenerative medicine can be used to reduce the after-effects of general treatments for burns including scarring, infection, and poor adhesion. Plastic surgery is performed using the near or distant tissue for skin flaps and grafts. However, regenerative plastic surgery uses a patients’ cells, which have the inherent capability to regenerate the required tissue. Therefore, increase in occurrences of obesity and diabetes coupled with a growing elderly population is contributing to the growth of the dermatology market.

Musculoskeletal: second largest segment of the global regenerative medicine market

The musculoskeletal segment accounted for 38.9% of the market in 2015. Musculoskeletal disorders occur when there are injuries to joints and soft tissue. These diseases can affect muscles, joints, cartilages, tendons, and supporting structures of the upper and lower limbs, neck, and back. Manufacturers in the market are focusing on developing therapeutic products for musculoskeletal disorders, which includes cellular therapies, and synthetic and biomaterial-based products. For instance, Mesoblast's MPC injections help replace lost cartilage and proteoglycan in degenerated intervertebral discs, and to regain its functional properties. Mesoblast is also developing new cellular therapies aimed at substituting, repairing, and encouraging tissue regeneration.

Ocular segment of the global regenerative medicine market

Ocular diseases affect the human eye and visual system. This segment ranges from infections to conditions that produce blindness and vision loss. Several conditions can affect the cornea, eyelids, retina, and optic nerve as age increases. Many cornea donors are aged; their corneas can be damaged or unsuitable for transplant. The use of regenerative medicines aimed to transform cornea surgeries and use a single cell of the cornea to treat multiple patients.

Browse related reports:

Purchase any three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact enquiry@technavio.com with your requirements and a link to our subscription platform.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
media@technavio.com

Release Summary

According to the latest research study released by Technavio, the regenerative medicine market in the US is expected to reach over USD 6973 million by 2020.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
media@technavio.com